Sort   by:  
 Page size 
TranscriptomicsGene expression profiles in resistant acute lymphoblastic leukemia
Treatment resistance as indicated by the presence of high levels of minimal residual disease (MRD) after induction therapy and induction consolidation is associated with a poor prognosis in childhood acute lymphoblastic leukemia (ALL). We hypothesized that treatment resistance is an intrinsic featur...
ORGANISM(S): Homo sapiens 
2006-01-18 | E-GEOD-4057 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of resistant acute lymphoblastic leukemia ALL
Treatment resistance as indicated by the presence of high levels of minimal residual disease (MRD) after induction therapy and induction consolidation is associated with a poor prognosis in childhood acute lymphoblastic leukemia (ALL). We hypothesized that treatment resistance is an intrinsic featur...
ORGANISM(S): Homo sapiens 
2005-11-09 | E-SMDB-2922 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human Downs syndrome with acute lymphoblastic pediatric leukemia (DS-ALL) patients
DS-ALL is a highly heterogeneous disease with predominance of an aberrant exp. of CRLF2 cooperating with mutated JAK2; Acute lymphoblastic pediatric leukemia specimens of Down's syndrome are examined for gene expression profiles and specific genetic aberrations. Gene expression profiling and specifi...
ORGANISM(S): Homo sapiens 
2010-01-15 | E-GEOD-17459 | biostudies-arrayexpress
GenomicsSuppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down Syndrome
Children with Down Syndrome (DS) are prone to development of high risk B-cell precursor ALL (DS-ALL) that differs genetically from most sporadic pediatric ALLs. Increased expression of CRLF2, the receptor to thymic stromal lymphopoietin (TSLP) characterizes about half of DS-ALLs and also a subgroup ...
EGAS00001002410 | EGA
GenomicsDAC for data acquired during the Down Syndrome acute lymphoblastic leukemia project. The project was performed with clinical samples of the AIEOP-BFM trial.
Data Access Committee EGAC00001000644
EGAC00001000644 | EGA
Genomicsena-DATASET-TAU-03-04-2017-19:28:40:078-460 - samples
Targeted resequencing of samples was done with TruSeq custom amplicon low input kit (TSCA-LI, Illumina). The oligo capture probes were designed to include a prefix of 8 random nucleotides at the 5 end of each probe. The assay is designed such that each targeted locus is annealed with two probes, res...
EGAD00001003275 | EGA
Genomicsena-DATASET-TAU-08-04-2017-14:02:11:924-149 - samples
Description not provided
EGAD00001003280 | EGA
Sort   by:  
 Page size